A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients
- Conditions
- HIV Infections
- Registration Number
- NCT00002410
- Lead Sponsor
- Dupont Merck
- Brief Summary
The purpose of this study is to compare the safety and effectiveness of three anti-HIV drug combinations. The three combinations are: (1) efavirenz (DMP 266) plus indinavir; (2) DMP 266 plus zidovudine (ZDV) plus lamivudine (3TC); and (3) indinavir plus ZDV plus 3TC. This study also examines the resistance HIV may have to these drugs and if these drugs are effective over a long period of time.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (40)
Phoenix Body Positive
🇺🇸Phoenix, Arizona, United States
Arizona Clinical Research Ctr Inc
🇺🇸Tucson, Arizona, United States
Richard Stryker
🇺🇸Beverly Hills, California, United States
Paul Cimoch
🇺🇸Irvine, California, United States
AIDS Healthcare Foundation
🇺🇸Los Angeles, California, United States
Kraus Med Group
🇺🇸Los Angeles, California, United States
Oasis Clinic / Martin Luther Jr Gen Hosp / King-Drew Med Ctr
🇺🇸Los Angeles, California, United States
Blick Med Associates
🇺🇸Stamford, Connecticut, United States
Novum Inc
🇺🇸Washington, District of Columbia, United States
Bach and Godofsky
🇺🇸Bradenton, Florida, United States
Scroll for more (30 remaining)Phoenix Body Positive🇺🇸Phoenix, Arizona, United States